# Effects of Rivaroxaban on Vascular FMD in Patients With Stable Atherosclerotic Vascular Diseases

Study · id `cardio:ct-nct06986369` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06986369](<https://clinicaltrials.gov/study/NCT06986369>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06986369

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.

## Technical summary

Registry record NCT06986369. Randomized; double masking; primary purpose treatment. Start 2021-05-04 (actual); primary completion 2023-08-28 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 140 participants (enrolled count; ClinicalTrials.gov record NCT06986369, source copy `cardio:ctgov-nct06986369-2025-05-23`, retrieved 2026-10-26)
- Started: 2021-05-04 (actual) (ClinicalTrials.gov record NCT06986369, source copy `cardio:ctgov-nct06986369-2025-05-23`, retrieved 2026-10-26)
- Primary completion: 2023-08-28 (actual) (ClinicalTrials.gov record NCT06986369, source copy `cardio:ctgov-nct06986369-2025-05-23`, retrieved 2026-10-26)
- Completion: 2024-03-01 (actual) (ClinicalTrials.gov record NCT06986369, source copy `cardio:ctgov-nct06986369-2025-05-23`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06986369, source copy `cardio:ctgov-nct06986369-2025-05-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06986369-2025-05-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Rivaroxaban on Vascular FMD in Patients With Stable Atherosclerotic Vascular Diseases
- Condition: Atherosclerosis, Coronary
- Intervention (Drug): Rivaroxaban 2.5 MG Oral Tablet \[Xarelto\]
- Lead sponsor: The University of Hong Kong
- Lead sponsor class: OTHER
- Collaborator: Bayer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Rivaroxaban (Xarelto) (`cardio:xarelto`)
- Registry intervention name is a brand that an FDA record in the corpus ties to this substance: Rivaroxaban (`cardio:rivaroxaban`)
- Registry lists this organization as the lead sponsor: The University of Hong Kong (`cardio:org-the-university-of-hong-kong`)
- Registry lists this organization as a collaborator: Bayer (`cardio:bayer`)

## Provenance

Content hash: 078d0a1bd51194abbac8ad60ff81f698d9f54ae9f33e45719535e1866bbc3b90
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
